<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Expanding tick exposure and molecular testing are driving year-round demand, creating opportunities for approved therapies, combination regimens, injectables and Asia-Pacific expansion.Dublin, Aug. 20, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6264748/babesiosis-treatment-market-share-analysis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=xmpjhb&amp;utm_campaign=2330840+-+Babesiosis+Treatment+2026-2031+-+Rising+Incidence+of+Tick-Borne+Diseases+Drives+Market+Growth&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="Babesiosis Treatment - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)">"Babesiosis Treatment - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)"</a> has been added to ResearchAndMarkets.com's offering. Global Babesiosis Treatment Market to Reach USD 120.65 Million by 2031 as Tick-Borne Infections Expand The global babesiosis treatment market is projected to grow from USD 86.40 million in 2025 to USD 91.29 million in 2026, reaching USD 120.65 million by 2031. The market is expected to register a compound annual growth rate of 5.72% between 2026 and 2031, supported by expanding tick habitats, longer transmission seasons, improved molecular diagnostics, and rising clinical awareness of tick-borne diseases. Longer Tick Seasons Increase Demand for Babesiosis Treatment The geographic range and active season of disease-carrying ticks continue to expand, increasing the population at risk of babesiosis. A 2025 study covering 1,130 patients from 1993 through 2024 reported annual case growth of 14.2%. It also found that the average transmission season in New England increased from 2.2 months before 2000 to 11 months in 2023. This extended exposure period is shifting healthcare requirements from seasonal preparation toward year-round diagnostic readiness and medicine availability. U.S. surveillance data also indicate that the number of states considered endemic for babesiosis doubled from seven to 13 after surveillance began in 2011. Locally acquired infections and infected ticks identified in mid-Atlantic states further demonstrate that the disease is moving beyond its historically established centers in the Northeast. Molecular Diagnostics Support Earlier Case Detection Advances in molecular testing are enabling healthcare providers to confirm infections earlier and initiate treatment before severe complications develop. A 2024 direct PCR study reported 98% concordance with laboratory PCR and generated results from whole blood in less than 60 minutes. Rapid workflows may help emergency departments evaluate Babesia alongside other tick-borne pathogens without relying exclusively on reference laboratories. A 2026 fluorescent recombinase polymerase amplification study detected Babesia microti at extremely low concentrations and confirmed 21 positive cases in a febrile patient cohort. Improved species identification is particularly important because infections caused by species such as Babesia divergens can result in severe disease among asplenic and immunocompromised patients. Faster, more accurate testing strengthens the pathway from clinical suspicion to confirmed diagnosis and appropriate prescribing. Lack of an FDA-Approved Therapy Remains a Market Constraint No medicine currently has a U.S. Food and Drug Administration-approved indication specifically for human babesiosis. Treatment therefore relies on clinical guidelines and off-label prescribing. The Infectious Diseases Society of America recommends atovaquone combined with azithromycin as the preferred regimen for most symptomatic patients, while clindamycin combined with quinine remains an alternative. The absence of a specifically approved therapy limits product differentiation, reimbursement certainty, and commercial incentives for dedicated drug development. Tafenoquine is being assessed through expanded-access research, and an October 2025 update reported that the first completed patient had no detectable Babesia. However, additional pivotal evidence would be required to support a potential regulatory submission. Combination Regimens and Injectable Therapies Gain Momentum Antiprotozoal agents represented 41.76% of the babesiosis treatment market by drug class in 2025, reflecting the central role of atovaquone in the preferred treatment regimen. Macrolide antibiotics, particularly azithromycin, also account for a significant share because of their routine use with atovaquone. Lincosamides and quinoline derivatives remain important for patients who cannot tolerate first-line therapy or require alternative treatment. Combination products are forecast to record the fastest drug-class growth, with a CAGR of 6.89% through 2031. This expansion reflects increased use of multi-drug protocols for severe, refractory, or relapsing infections. A 2025 Massachusetts multicenter cohort found that 8% of hospitalized patients received triple therapy with atovaquone, azithromycin, and clindamycin. Salvage combinations are also being used in selected immunocompromised patients with persistent infection. Oral administration accounted for 76.16% of the market in 2026, supported by the widespread use of oral atovaquone and azithromycin for mild-to-moderate cases. Oral therapy enables outpatient management and allows hospitalized patients to continue treatment following discharge. Broad generic availability also supports access and price competition. Parenteral administration is projected to grow at a CAGR of 6.91% through 2031. Demand is being driven by severe disease, hospitalization, and treatment requirements among older or immunocompromised patients. Intravenous azithromycin and clindamycin may be used during initial hospital care before patients transition to oral therapy. Longer transmission seasons are also encouraging hospitals to maintain injectable inventories throughout the year. North America Leads While Asia-Pacific Records the Fastest Growth North America held 53.17% of the global babesiosis treatment market in 2025, supported by established surveillance systems, blood safety requirements, diagnostic access, and treatment availability. The United States reported 3,586 cases in 2023, including 1,169 in New York and 841 in Massachusetts. Evidence of locally acquired infections in Maryland, Virginia, and West Virginia highlights the disease's continued geographic expansion. Europe represents a smaller share but faces a greater concentration of severe B. divergens infections among asplenic patients, increasing the need for rapid diagnosis and intensive hospital care. Meanwhile, Asia-Pacific is forecast to achieve the fastest regional growth, with a CAGR of 6.68% through 2031. China is the region's principal contributor, with more than 300 symptomatic human cases documented across 17 provinces through 2025. Growing surveillance, blood donor screening research, and the future development of standardized clinical pathways are expected to create additional opportunities across the region. Key Topics Covered: 1 INTRODUCTION 1.1 Study Assumptions and Market Definition 1.2 Scope of the Study 2 RESEARCH METHODOLOGY 3 EXECUTIVE SUMMARY 4 MARKET LANDSCAPE 4.1 Market Overview 4.2 Market Drivers 4.2.1 Expanding Tick-Borne Exposure and Geographic Range 4.2.2 Rising Case Detection Through Molecular Testing 4.2.3 Mandatory Blood Donor Screening in U.S. Endemic States 4.2.4 Growing Immunocompromised and Older Patient Pool 4.2.5 Persistent Relapsing Disease Creating Demand for New Regimens 4.2.6 Cross-Species One Health Surveillance and Veterinary Treatment Demand 4.3 Market Restraints 4.3.1 Absence of an FDA-Approved Human Babesiosis Treatment 4.3.2 Low Disease Awareness and Frequent Misdiagnosis 4.3.3 Atovaquone Resistance and Relapse in Immunocompromised Hosts 4.3.4 Low Commercial Incentive for Rare-Disease Drug Development 4.4 Supply Chain Analysis 4.5 Regulatory Landscape 4.6 Technological Outlook 4.7 Porter's Five Forces Analysis 4.7.1 Bargaining Power of Suppliers 4.7.2 Bargaining Power of Buyers 4.7.3 Threat of New Entrants 4.7.4 Threat of Substitutes 4.7.5 Competitive Rivalry 5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD) 5.1 By Drug Class 5.1.1 Antiprotozoal Agents 5.1.2 Macrolide Antibiotics 5.1.3 Lincosamide Antibiotics 5.1.4 Quinoline Derivatives 5.1.5 Combination Products 5.1.6 Others 5.2 By Route of Administration 5.2.1 Oral 5.2.2 Parenteral 5.3 By Patient Population 5.3.1 Pediatric 5.3.2 Adults 5.3.3 Geriatric 5.4 By Distribution Channel 5.4.1 Hospital Pharmacies 5.4.2 Retail Pharmacies 5.4.3 Online Pharmacies 5.4.4 Specialty Pharmacies 5.5 By Geography 5.5.1 North America 5.5.1.1 United States 5.5.1.2 Canada 5.5.1.3 Mexico 5.5.2 Europe 5.5.2.1 Germany 5.5.2.2 United Kingdom 5.5.2.3 France 5.5.2.4 Italy 5.5.2.5 Spain 5.5.2.6 Rest of Europe 5.5.3 Asia-Pacific 5.5.3.1 China 5.5.3.2 Japan 5.5.3.3 India 5.5.3.4 Australia 5.5.3.5 South Korea 5.5.3.6 Rest of Asia-Pacific 5.5.4 Middle East and Africa 5.5.4.1 GCC 5.5.4.2 South Africa 5.5.4.3 Rest of Middle East and Africa 5.5.5 South America 5.5.5.1 Brazil 5.5.5.2 Argentina 5.5.5.3 Rest of South America 6 COMPETITIVE LANDSCAPE 6.1 Market Concentration 6.2 Market Share Analysis 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments) 6.3.1 Alkem Laboratories 6.3.2 Amneal Pharmaceuticals, Inc. 6.3.3 Apotex Inc. 6.3.4 Aurobindo Pharma Limited 6.3.5 Bionpharma, Inc. 6.3.6 Cipla Limited 6.3.7 Dr. Reddy's Laboratories 6.3.8 Endo International 6.3.9 Fresenius Kabi AG 6.3.10 Glenmark Pharmaceuticals Ltd. 6.3.11 GSK plc 6.3.12 Hetero Drugs Limited 6.3.13 Hikma Pharmaceuticals PLC 6.3.14 Lupin Limited 6.3.15 Pfizer Inc. 6.3.16 Sandoz Group AG 6.3.17 Sun Pharmaceutical Industries Limited 6.3.18 Teva Pharmaceutical Industries Ltd. 6.3.19 Viatris Inc. 6.3.20 Zydus Lifesciences 7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK 7.1 White-Space and Unmet-Need Assessment For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6264748/babesiosis-treatment-market-share-analysis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=xmpjhb&amp;utm_campaign=2330840+-+Babesiosis+Treatment+2026-2031+-+Rising+Incidence+of+Tick-Borne+Diseases+Drives+Market+Growth&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/bjghmp</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/ZDYzYmIzNTgtNWM5MS00MmM1LWE1NjUtMjllODUzZmE5NjJmLTEwMjY3MzctMjAyNi0wOC0yMC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Babesiosis Treatment 2026-2031 - Rising Incidence of Tick-Borne Diseases Drives Market Growth

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn